Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Sumitomo Dainippon Pharma Co ( (JP:4506) ) has shared an update.
Sumitomo Pharma has announced ‘Reboot 2027,’ a strategic plan for FY2025-FY2027, aiming to stabilize its revenue base and enhance its position as an R&D-driven pharmaceutical company. The plan includes financial targets such as expanding sales of key products and reducing debt, alongside initiatives to innovate in oncology and regenerative medicine. The company seeks to improve its value creation cycle and establish a distinctive global presence, with a focus on strategic growth and innovation.
The most recent analyst rating on (JP:4506) stock is a Hold with a Yen460.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.
More about Sumitomo Dainippon Pharma Co
Sumitomo Pharma Co., Ltd. operates in the pharmaceutical industry, focusing on research and development-driven initiatives. The company offers a range of products, including ORGOVYX, GEMTESA, MYFEMBREE, and RETHYMIC, and is committed to advancing in fields like oncology, regenerative medicine, and cell therapy. Sumitomo Pharma aims to establish a strong global presence and contribute to healthcare improvements worldwide.
Average Trading Volume: 5,624,664
Technical Sentiment Signal: Buy
Current Market Cap: Yen383B
See more insights into 4506 stock on TipRanks’ Stock Analysis page.